Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine

On:
FILE PHOTO: Vials labelled “VACCINE Coronavirus COVID-19” and a syringe are seen in front of a displayed Japanese flag in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration

TOKYO (Reuters) – Daiichi Sankyo Co said on Friday it submitted its mRNA-based COVID-19 vaccine for regulatory approval in Japan.

Approval would give Japan a home-grown mRNA vaccine of the type that have made up the bulk of its COVID inoculations so far. The vaccine known as DS-5670 is being proposed as a booster shot, Daiichi Sankyo said in a statement.

In a trial of about 5,000 Japanese adults, those who received the vaccine developed levels of COVID antibodies that were as good as or better than those of people who got other mRNA shots, the company said in November.

Daiichi Sankyo said it plans to move forward to develop DS-5670 to target the Omicron strain of the coronavirus.

Japan has relied mainly on imports of shots developed by U.S. drugmakers Pfizer Inc and Moderna Inc.

Source: Read Full Article

Lates News:
  1. Treasuries Come Under Pressure After Initial Move To The Upside
  2. These Are the Top 10 Leveraged Commodities Trading ETFs
  3. The Fact That People Still Push the Long-Discredited 4 Percent Rule Shows the Irrationality of Buy-and-Hold
  4. Wednesday’s Top Analyst Upgrades and Downgrades: APA, Edwards Lifesciences, Johnson & Johnson, Match, Medtronic, Netflix, Walmart and More
  5. 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income